Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma

Jia Hui Huang; Shu Huey Chen; Yu Mei Liao; Yu Chien Kao; Wan Ling Ho; Hsi Chang; Min Lan Tsai; Hsin Lun Lee; Chia Chun Kuo; Sung Hui Tseng; Chia Yau Chang; Kevin Li Chun Hsieh; Long Sheng Lu; Yin Ju Chen; Jeng Fong Chiou; Tsung Han Hsieh; Yun Ru Liu; Wayne Hsu; Wei Tang Li; Yu Chung Wu; Wei Ciao Wu; Jinn Li Wang; Jia Jia Tsai; Keita Terashima; Chikako Kiyotani; Tai Tong Wong; James S. Miser; Yen Lin Liu

doi:10.3390/jpm13040668

Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma

Jia Hui Huang, Shu Huey Chen, Yu Mei Liao, Yu Chien Kao, Wan Ling Ho, Hsi Chang, Min Lan Tsai, Hsin Lun Lee, Chia Chun Kuo, Sung Hui Tseng, Chia Yau Chang, Kevin Li Chun Hsieh, Long Sheng Lu, Yin Ju Chen, Jeng Fong Chiou, Tsung Han Hsieh, Yun Ru Liu, Wayne Hsu, Wei Tang Li, Yu Chung WuWei Ciao Wu, Jinn Li Wang, Jia Jia Tsai, Keita Terashima, Chikako Kiyotani, Tai Tong Wong, James S. Miser, Yen Lin Liu^*

^*此作品的通信作者

研究成果: 期刊稿件 › 文章 › 同行評審

摘要

Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m²), doxorubicin (75 mg/m²), and cyclophosphamide (1200–2200 mg/m²) (VDC) alternating with a regimen of ifosfamide (9000 mg/m²) and etoposide (500 mg/m²) (IE), with filgrastim (5–10 mcg/kg/day) between cycles. Carboplatin (800 mg/m²) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15–24 days. Median nadirs (IQR) were neutrophil count, 134 (30–396) × 10⁶/L at day 11 (10–12), recovery by day 15 (14–17) and platelet count, 35 (23–83) × 10⁹/L at day 11 (10–13), recovery by day 17 (14–21). Fever and bacteremia were observed in 36% and 8% of cycles, respectively. The diagnoses were Ewing sarcoma (6), rhabdomyosarcoma (3), myoepithelial carcinoma (1), malignant peripheral nerve sheath tumor (1), and CIC-DUX4 Sarcoma (1). Seven of the nine patients with measurable tumors responded (one CR and six PR). Interval-compressed chemotherapy is feasible in the treatment of Asian children and young adults with sarcomas.

原文	英語
文章編號	668
期刊	Journal of Personalized Medicine
卷	13
發行號	4
DOIs	https://doi.org/10.3390/jpm13040668
出版狀態	已出版 - 14 04 2023
對外發佈	是

文獻附註

Publisher Copyright:
© 2023 by the authors.

存取文件

10.3390/jpm13040668

其它文件與鏈接

Link to publication in Scopus

引用此

Huang, J. H., Chen, S. H., Liao, Y. M., Kao, Y. C., Ho, W. L., Chang, H., Tsai, M. L., Lee, H. L., Kuo, C. C., Tseng, S. H., Chang, C. Y., Hsieh, K. L. C., Lu, L. S., Chen, Y. J., Chiou, J. F., Hsieh, T. H., Liu, Y. R., Hsu, W., Li, W. T., ... Liu, Y. L. (2023). Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma. Journal of Personalized Medicine, 13(4), 文章 668. https://doi.org/10.3390/jpm13040668

@article{8be463331808457cac4e6b317da4c615,

title = "Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma",

abstract = "Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1200–2200 mg/m2) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2) and etoposide (500 mg/m2) (IE), with filgrastim (5–10 mcg/kg/day) between cycles. Carboplatin (800 mg/m2) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15–24 days. Median nadirs (IQR) were neutrophil count, 134 (30–396) × 106/L at day 11 (10–12), recovery by day 15 (14–17) and platelet count, 35 (23–83) × 109/L at day 11 (10–13), recovery by day 17 (14–21). Fever and bacteremia were observed in 36% and 8% of cycles, respectively. The diagnoses were Ewing sarcoma (6), rhabdomyosarcoma (3), myoepithelial carcinoma (1), malignant peripheral nerve sheath tumor (1), and CIC-DUX4 Sarcoma (1). Seven of the nine patients with measurable tumors responded (one CR and six PR). Interval-compressed chemotherapy is feasible in the treatment of Asian children and young adults with sarcomas.",

keywords = "VDC/IE, adolescent and young adult, children, granulocyte colony-stimulating factor, interval-compressed chemotherapy, round cell sarcoma",

author = "Huang, {Jia Hui} and Chen, {Shu Huey} and Liao, {Yu Mei} and Kao, {Yu Chien} and Ho, {Wan Ling} and Hsi Chang and Tsai, {Min Lan} and Lee, {Hsin Lun} and Kuo, {Chia Chun} and Tseng, {Sung Hui} and Chang, {Chia Yau} and Hsieh, {Kevin Li Chun} and Lu, {Long Sheng} and Chen, {Yin Ju} and Chiou, {Jeng Fong} and Hsieh, {Tsung Han} and Liu, {Yun Ru} and Wayne Hsu and Li, {Wei Tang} and Wu, {Yu Chung} and Wu, {Wei Ciao} and Wang, {Jinn Li} and Tsai, {Jia Jia} and Keita Terashima and Chikako Kiyotani and Wong, {Tai Tong} and Miser, {James S.} and Liu, {Yen Lin}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = apr,

day = "14",

doi = "10.3390/jpm13040668",

language = "英语",

volume = "13",

journal = "Journal of Personalized Medicine",

issn = "2075-4426",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

Huang, JH, Chen, SH, Liao, YM, Kao, YC, Ho, WL, Chang, H, Tsai, ML, Lee, HL, Kuo, CC, Tseng, SH, Chang, CY, Hsieh, KLC, Lu, LS, Chen, YJ, Chiou, JF, Hsieh, TH, Liu, YR, Hsu, W, Li, WT, Wu, YC, Wu, WC, Wang, JL, Tsai, JJ, Terashima, K, Kiyotani, C, Wong, TT, Miser, JS & Liu, YL 2023, 'Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma', Journal of Personalized Medicine, 卷 13, 編號 4, 668. https://doi.org/10.3390/jpm13040668

TY - JOUR

T1 - Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma

AU - Huang, Jia Hui

AU - Chen, Shu Huey

AU - Liao, Yu Mei

AU - Kao, Yu Chien

AU - Ho, Wan Ling

AU - Chang, Hsi

AU - Tsai, Min Lan

AU - Lee, Hsin Lun

AU - Kuo, Chia Chun

AU - Tseng, Sung Hui

AU - Chang, Chia Yau

AU - Hsieh, Kevin Li Chun

AU - Lu, Long Sheng

AU - Chen, Yin Ju

AU - Chiou, Jeng Fong

AU - Hsieh, Tsung Han

AU - Liu, Yun Ru

AU - Hsu, Wayne

AU - Li, Wei Tang

AU - Wu, Yu Chung

AU - Wu, Wei Ciao

AU - Wang, Jinn Li

AU - Tsai, Jia Jia

AU - Terashima, Keita

AU - Kiyotani, Chikako

AU - Wong, Tai Tong

AU - Miser, James S.

AU - Liu, Yen Lin

PY - 2023/4/14

Y1 - 2023/4/14

N2 - Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1200–2200 mg/m2) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2) and etoposide (500 mg/m2) (IE), with filgrastim (5–10 mcg/kg/day) between cycles. Carboplatin (800 mg/m2) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15–24 days. Median nadirs (IQR) were neutrophil count, 134 (30–396) × 106/L at day 11 (10–12), recovery by day 15 (14–17) and platelet count, 35 (23–83) × 109/L at day 11 (10–13), recovery by day 17 (14–21). Fever and bacteremia were observed in 36% and 8% of cycles, respectively. The diagnoses were Ewing sarcoma (6), rhabdomyosarcoma (3), myoepithelial carcinoma (1), malignant peripheral nerve sheath tumor (1), and CIC-DUX4 Sarcoma (1). Seven of the nine patients with measurable tumors responded (one CR and six PR). Interval-compressed chemotherapy is feasible in the treatment of Asian children and young adults with sarcomas.

AB - Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1200–2200 mg/m2) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2) and etoposide (500 mg/m2) (IE), with filgrastim (5–10 mcg/kg/day) between cycles. Carboplatin (800 mg/m2) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15–24 days. Median nadirs (IQR) were neutrophil count, 134 (30–396) × 106/L at day 11 (10–12), recovery by day 15 (14–17) and platelet count, 35 (23–83) × 109/L at day 11 (10–13), recovery by day 17 (14–21). Fever and bacteremia were observed in 36% and 8% of cycles, respectively. The diagnoses were Ewing sarcoma (6), rhabdomyosarcoma (3), myoepithelial carcinoma (1), malignant peripheral nerve sheath tumor (1), and CIC-DUX4 Sarcoma (1). Seven of the nine patients with measurable tumors responded (one CR and six PR). Interval-compressed chemotherapy is feasible in the treatment of Asian children and young adults with sarcomas.

KW - VDC/IE

KW - adolescent and young adult

KW - children

KW - granulocyte colony-stimulating factor

KW - interval-compressed chemotherapy

KW - round cell sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85154579553&partnerID=8YFLogxK

U2 - 10.3390/jpm13040668

DO - 10.3390/jpm13040668

M3 - 文章

C2 - 37109054

AN - SCOPUS:85154579553

SN - 2075-4426

VL - 13

JO - Journal of Personalized Medicine

JF - Journal of Personalized Medicine

IS - 4

M1 - 668

ER -

Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma

摘要

文獻附註

存取文件

其它文件與鏈接

指紋

引用此